Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of NEULAND LABS. For more details, see the NEULAND LABS quarterly results and NEULAND LABS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -4.0 |
No. of shares | m | 12.83 |
1 Week | % | 18.1 |
1 Month | % | 17.3 |
1 Year | % | 257.9 |
52 week H/L | Rs | 7,794.0/1,947.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
NEULAND LABS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 828 | 754 | 2,350 | 2,840 | 2,004 | |
Low | Rs | 431 | 247 | 260 | 1,000 | 966 | |
Sales per share (Unadj.) | Rs | 519.7 | 594.5 | 730.3 | 741.3 | 928.4 | |
Earnings per share (Unadj.) | Rs | 12.8 | 12.6 | 62.8 | 49.7 | 127.4 | |
Diluted earnings per share | Rs | 12.8 | 12.6 | 62.8 | 49.7 | 127.5 | |
Cash flow per share (Unadj.) | Rs | 33.0 | 37.0 | 93.8 | 88.0 | 168.6 | |
Dividends per share (Unadj.) | Rs | 1.20 | 2.00 | 5.00 | 5.00 | 10.00 | |
Adj. dividends per share | Rs | 1.20 | 2.00 | 5.00 | 5.00 | 10.00 | |
Avg Dividend yield | % | 0.2 | 0.4 | 0.4 | 0.3 | 0.7 | |
Book value per share (Unadj.) | Rs | 545.1 | 553.4 | 613.0 | 655.1 | 774.8 | |
Adj. book value per share | Rs | 545.1 | 553.4 | 613.0 | 655.1 | 774.8 | |
Shares outstanding (eoy) | m | 12.83 | 12.83 | 12.83 | 12.83 | 12.83 | |
Price / Sales ratio | x | 1.2 | 0.8 | 1.8 | 2.6 | 1.6 | |
Avg P/E ratio | x | 49.1 | 39.6 | 20.8 | 38.6 | 11.7 | |
P/CF ratio (eoy) | x | 19.1 | 13.5 | 13.9 | 21.8 | 8.8 | |
Price / Book Value ratio | x | 1.2 | 0.9 | 2.1 | 2.9 | 1.9 | |
Dividend payout | % | 9.4 | 15.8 | 8.0 | 10.1 | 7.8 | |
Avg Mkt Cap | Rs m | 8,078 | 6,421 | 16,746 | 24,633 | 19,052 | |
Total wages/salary | Rs m | 1,105 | 1,236 | 1,497 | 1,825 | 2,018 |
NEULAND LABS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 6,668 | 7,627 | 9,369 | 9,511 | 11,912 | |
Other income | Rs m | 35 | 39 | 161 | 21 | 97 | |
Total revenues | Rs m | 6,703 | 7,666 | 9,530 | 9,532 | 12,009 | |
Gross profit | Rs m | 584 | 1,019 | 1,468 | 1,426 | 2,718 | |
Depreciation | Rs m | 259 | 313 | 397 | 490 | 528 | |
Interest | Rs m | 157 | 216 | 179 | 135 | 131 | |
Profit before tax | Rs m | 203 | 529 | 1,053 | 822 | 2,157 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 39 | 367 | 247 | 183 | 522 | |
Profit after tax | Rs m | 164 | 162 | 806 | 638 | 1,635 | |
Gross profit margin | % | 8.8 | 13.4 | 15.7 | 15.0 | 22.8 | |
Effective tax rate | % | 19.2 | 69.4 | 23.5 | 22.3 | 24.2 | |
Net profit margin | % | 2.5 | 2.1 | 8.6 | 6.7 | 13.7 |
NEULAND LABS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 4,535 | 5,152 | 5,496 | 5,808 | 7,609 | |
Current liabilities | Rs m | 3,270 | 3,576 | 3,685 | 3,632 | 4,390 | |
Net working cap to sales | % | 19.0 | 20.7 | 19.3 | 22.9 | 27.0 | |
Current ratio | x | 1.4 | 1.4 | 1.5 | 1.6 | 1.7 | |
Inventory Days | Days | 21 | 22 | 19 | 7 | 6 | |
Debtors Days | Days | 898 | 909 | 848 | 899 | 1,109 | |
Net fixed assets | Rs m | 6,769 | 7,158 | 7,752 | 8,027 | 8,189 | |
Share capital | Rs m | 129 | 129 | 129 | 129 | 129 | |
"Free" reserves | Rs m | 6,864 | 6,971 | 7,736 | 8,276 | 9,812 | |
Net worth | Rs m | 6,993 | 7,100 | 7,865 | 8,405 | 9,941 | |
Long term debt | Rs m | 607 | 774 | 881 | 1,042 | 742 | |
Total assets | Rs m | 11,304 | 12,310 | 13,248 | 13,835 | 15,798 | |
Interest coverage | x | 2.3 | 3.5 | 6.9 | 7.1 | 17.5 | |
Debt to equity ratio | x | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
Sales to assets ratio | x | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | |
Return on assets | % | 2.8 | 3.1 | 7.4 | 5.6 | 11.2 | |
Return on equity | % | 2.4 | 2.3 | 10.3 | 7.6 | 16.4 | |
Return on capital | % | 4.7 | 9.5 | 14.1 | 10.1 | 21.4 | |
Exports to sales | % | 72.5 | 68.0 | 77.8 | 72.1 | 73.5 | |
Imports to sales | % | 25.2 | 20.9 | 29.5 | 17.0 | 15.1 | |
Exports (fob) | Rs m | 4,835 | 5,187 | 7,292 | 6,858 | 8,750 | |
Imports (cif) | Rs m | 1,681 | 1,593 | 2,765 | 1,613 | 1,804 | |
Fx inflow | Rs m | 4,835 | 5,187 | 7,292 | 6,858 | 8,750 | |
Fx outflow | Rs m | 1,681 | 1,593 | 2,765 | 1,613 | 1,804 | |
Net fx | Rs m | 3,154 | 3,594 | 4,527 | 5,245 | 6,946 |
NEULAND LABS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 699 | 573 | 1,894 | 604 | 2,372 | |
From Investments | Rs m | -772 | -487 | -844 | -955 | -615 | |
From Financial Activity | Rs m | 120 | -55 | -1,137 | 377 | -1,358 | |
Net Cashflow | Rs m | 47 | 33 | -88 | 27 | 403 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Davuluri Rama Mohan Rao | COMP SEC: Sarada Bhamidipati | YEAR OF INC: 1984 | BSE CODE: 524558 | FV (Rs): 10 | DIV YIELD (%): 0.1 |
Read: NEULAND LABS 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare NEULAND LABS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
It was indeed a volatile trading session for Indian share markets yesterday.